These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24799036)

  • 1. JAK-cytokine receptor recognition, unboxed.
    McNally R; Eck MJ
    Nat Struct Mol Biol; 2014 May; 21(5):431-3. PubMed ID: 24799036
    [No Abstract]   [Full Text] [Related]  

  • 2. Structural basis of recognition of interferon-α receptor by tyrosine kinase 2.
    Wallweber HJ; Tam C; Franke Y; Starovasnik MA; Lupardus PJ
    Nat Struct Mol Biol; 2014 May; 21(5):443-8. PubMed ID: 24704786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
    Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
    J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6.
    Chrencik JE; Patny A; Leung IK; Korniski B; Emmons TL; Hall T; Weinberg RA; Gormley JA; Williams JM; Day JE; Hirsch JL; Kiefer JR; Leone JW; Fischer HD; Sommers CD; Huang HC; Jacobsen EJ; Tenbrink RE; Tomasselli AG; Benson TE
    J Mol Biol; 2010 Jul; 400(3):413-33. PubMed ID: 20478313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific contribution of Tyk2 JH regions to the binding and the expression of the interferon alpha/beta receptor component IFNAR1.
    Richter MF; Duménil G; Uzé G; Fellous M; Pellegrini S
    J Biol Chem; 1998 Sep; 273(38):24723-9. PubMed ID: 9733772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new regulatory switch in a JAK protein kinase.
    Tsui V; Gibbons P; Ultsch M; Mortara K; Chang C; Blair W; Pulk R; Stanley M; Starovasnik M; Williams D; Lamers M; Leonard P; Magnuson S; Liang J; Eigenbrot C
    Proteins; 2011 Feb; 79(2):393-401. PubMed ID: 21117080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-modulation of type 1 interferon responses by receptor cross-competition for a shared Jak kinase.
    Dondi E; Pattyn E; Lutfalla G; Van Ostade X; Uzé G; Pellegrini S; Tavernier J
    J Biol Chem; 2001 Dec; 276(50):47004-12. PubMed ID: 11602573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha.
    Li S; Labrecque S; Gauzzi MC; Cuddihy AR; Wong AH; Pellegrini S; Matlashewski GJ; Koromilas AE
    Oncogene; 1999 Oct; 18(42):5727-37. PubMed ID: 10523853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definition of the interferon-alpha receptor-binding domain on the TYK2 kinase.
    Yan H; Piazza F; Krishnan K; Pine R; Krolewski JJ
    J Biol Chem; 1998 Feb; 273(7):4046-51. PubMed ID: 9461596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct binding to and tyrosine phosphorylation of the alpha subunit of the type I interferon receptor by p135tyk2 tyrosine kinase.
    Colamonici O; Yan H; Domanski P; Handa R; Smalley D; Mullersman J; Witte M; Krishnan K; Krolewski J
    Mol Cell Biol; 1994 Dec; 14(12):8133-42. PubMed ID: 7526154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.
    Lupardus PJ; Ultsch M; Wallweber H; Bir Kohli P; Johnson AR; Eigenbrot C
    Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8025-30. PubMed ID: 24843152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of an alpha interferon receptor 1 subunit (IFNaR1) domain required for TYK2 binding and signal transduction.
    Yan H; Krishnan K; Lim JT; Contillo LG; Krolewski JJ
    Mol Cell Biol; 1996 May; 16(5):2074-82. PubMed ID: 8628273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.
    Gerstenberger BS; Ambler C; Arnold EP; Banker ME; Brown MF; Clark JD; Dermenci A; Dowty ME; Fensome A; Fish S; Hayward MM; Hegen M; Hollingshead BD; Knafels JD; Lin DW; Lin TH; Owen DR; Saiah E; Sharma R; Vajdos FF; Xing L; Yang X; Yang X; Wright SW
    J Med Chem; 2020 Nov; 63(22):13561-13577. PubMed ID: 32787094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of hybrid type I interferons in cells lacking Tyk2: a common region of IFN-alpha 8 induces a response, but IFN-alpha2/8 hybrids can behave like IFN-beta.
    Platis D; Foster GR
    J Interferon Cytokine Res; 2003 Nov; 23(11):655-66. PubMed ID: 14651780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alpha/beta and for signal transduction.
    Velazquez L; Mogensen KE; Barbieri G; Fellous M; Uzé G; Pellegrini S
    J Biol Chem; 1995 Feb; 270(7):3327-34. PubMed ID: 7531704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of a peptide inhibitor of tyrosine kinase 2.
    Works MG; Song B; Kibler P; Tanga MJ; Galande AK; D'Andrea A
    Protein Pept Lett; 2014 May; 21(5):419-25. PubMed ID: 24304386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.
    Tokarski JS; Zupa-Fernandez A; Tredup JA; Pike K; Chang C; Xie D; Cheng L; Pedicord D; Muckelbauer J; Johnson SR; Wu S; Edavettal SC; Hong Y; Witmer MR; Elkin LL; Blat Y; Pitts WJ; Weinstein DS; Burke JR
    J Biol Chem; 2015 Apr; 290(17):11061-74. PubMed ID: 25762719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
    Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
    Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TYK2 Variants in B-Acute Lymphoblastic Leukaemia.
    Turrubiartes-Martínez E; Bodega-Mayor I; Delgado-Wicke P; Molina-Jiménez F; Casique-Aguirre D; González-Andrade M; Rapado I; Camós M; Díaz-de-Heredia C; Barragán E; Ramírez-Orellana M; Aguado B; Figuera Á; Martínez-López J; Fernández-Ruiz E
    Genes (Basel); 2020 Nov; 11(12):. PubMed ID: 33260630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinase-deficient forms of Jak1 and Tyk2 inhibit interferon alpha signaling in a dominant manner.
    Krishnan K; Pine R; Krolewski JJ
    Eur J Biochem; 1997 Jul; 247(1):298-305. PubMed ID: 9249040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.